Trans-sodium crocetinate provides neuroprotection against cerebral ischemia and reperfusion in obese mice

Journal of Neuroscience Research

Volumn 93, Issue 4, 2015, Pages 615-622

  Deng, Jiao ^a,b   Xiong, Lize ^b   Zuo, Zhiyi ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Focal brain ischemia; Hemorrhagic transformation; Matrix metalloproteinase 9; Neuroprotection; Obesity; Trans sodium crocetinate

Indexed keywords

4 HYDROXYNONENAL; CD11B ANTIGEN; CROCETIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; 3-NITROTYROSINE; 4-HYDROXY-2-NONENAL; ALDEHYDE; CYTOKINE; MATRIX METALLOPROTEINASE; NEUROPROTECTIVE AGENT; RETINOL; TRANS-SODIUM CROCETINATE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TISSUE; CORPUS STRIATUM; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; LIPID DIET; MALE; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY;

ALDEHYDES; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MATRIX METALLOPROTEINASES; MICE; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; OBESITY; OXIDATIVE STRESS; REPERFUSION; TYROSINE; VITAMIN A;

EID: 84922983676     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23522     Document Type: Article

References (33)

1. Balci K, Utku U, Asil T, Celik Y. 2011. Ischemic stroke in young adults: risk factors, subtypes, and prognosis. Neurologist 17:16-20.
2. Bhatnagar D, Soran H, Durrington PN. 2008. Hypercholesterolaemia and its management. BMJ 337:a993.
3. Buckman LB, Hasty AH, Flaherty DK, Buckman CT, Thompson MM, Matlock BK, Weller K, Ellacott KL. 2014. Obesity induced by a high-fat diet is associated with increased immune cell entry into the central nervous system. Brain Behav Immun 35:33-42.
4. Deng J, Feng J, Feng C, Xiong L, Zuo Z. 2014. Critical role of matrix metalloprotease-9 in chronic high-fat diet-induced cerebral vascular remodeling and increase of ischemic brain injury in mice. Cardiovasc Res 103:473-84.
5. Dhungana H, Rolova T, Savchenko E, Wojciechowski S, Savolainen K, Ruotsalainen AK, Sullivan PM, Koistinaho J, Malm T. 2013. Western-type diet modulates inflammatory responses and impairs functional outcome following permanent middle cerebral artery occlusion in aged mice expressing the human apolipoprotein E4 allele. J Neuroinflammation 10:102.
6. Gainer JL. 2008. Trans-sodium crocetinate for treating hypoxia/ischemia. Expert Opin Invest Drugs 17:917-924.
7. Gainer JL, Rudolph DB, Caraway DL. 1993. The effect of crocetin on hemorrhagic shock in rats. Circ Shock 41:1-7.
8. Holloway GM, Gainer JL. 1988. The carotenoid crocetin enhances pulmonary oxygenation. J Appl Physiol 65:683-686.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. 1989. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910.
10. Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, Massasa E, Cloonan L, Gilson A, Capozzo K, Cortellini L, Ois A, Cuadrado-Godia E, Rodriguez-Campello A, Furie KL, Roquer J, Rosand J, Rost NS. 2010. Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 41:437-442.
11. Katayama Y, Horigome H, Takahashi H, Tanaka K, Yoshinaga M. 2010. Determinants of blood rheology in healthy adults and children using the microchannel array flow analyzer. Clin Appl Thromb Hemost 16:414-421.
12. Kopelman PG. 2000. Obesity as a medical problem. Nature 404:635-643.
13. Lapchak PA. 2010. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. Brain Res 1309:136-145.
14. Li H, Yin J, Li L, Deng J, Feng C, Zuo Z. 2013. Isoflurane postconditioning reduces ischemia-induced nuclear factor-kappaB activation and interleukin 1beta production to provide neuroprotection in rats and mice. Neurobiol Dis 54:216-224.
15. Li L, Zuo Z. 2011. Glutamate transporter type 3 knockout reduces brain tolerance to focal brain ischemia in mice. J Cereb Blood Flow Metab 31:1283-1292.
16. Lipton P. 1999. Ischemic cell death in brain neurons. Physiol Rev 79:1431-1568.
17. Manabe H, Okonkwo DO, Gainer JL, Clarke RH, Lee KS. 2010. Protection against focal ischemic injury to the brain by trans-sodium crocetinate. Laboratory investigation. J Neurosurg 113:802-809.
18. Martin JA, Smith BL, Matthews TJ, Ventura SJ. 1999. Births and deaths: preliminary data for 1998. Natl Vital Stat Rep 47:1-45.
19. Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. 2007. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 38:281-285.
20. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J. 2001. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767.
21. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. 2003. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598-603.
22. Okonkwo DO, Wagner J, Melon DE, Alden T, Stone JR, Helm GA, Jane JA Sr. 2003. Trans-sodium crocetinate increases oxygen delivery to brain parenchyma in rats on oxygen supplementation. Neurosci Lett 352:97-100.
23. Olsen TS, Christensen RH, Kammersgaard LP, Andersen KK. 2007. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 38:2646-2651.
24. Olszynski K, Zimowska M. 2009. [Structure and function of matrix metalloproteinases]. Postepy Biochem 55:76-84.
25. Purkayastha S, Cai D. 2013. Neuroinflammatory basis of metabolic syndrome. Mol Metab 2:356-363.
26. Sacco RL, Liao JK. 2005. Drug insight: statins and stroke. Nat Clin Pract Cardiovasc Med 2:576-584.
27. Stanimirovic D, Satoh K. 2000. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 10:113-126.
28. Stennett AK, Dempsey GL, Gainer JL. 2006. Trans-sodium crocetinate and diffusion enhancement. J Phys Chem B 110:18078-18080.
29. Stennett AK, Murray RJ, Roy JW, Gainer JL. 2007. Trans-sodium crocetinate and hemorrhagic shock. Shock 28:339-344.
30. Sumii T, Lo EH. 2002. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-836.
31. Tu YF, Tsai YS, Wang LW, Wu HC, Huang CC, Ho CJ. 2011. Overweight worsens apoptosis, neuroinflammation, and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J Neuroinflammation 8:40.
32. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH. 2000. Effects of matrix metalloproteinase-9 gene knockout on morphological and motor outcomes after traumatic brain injury. J Neurosci 20:7037-7042.
33. Zheng S, Zuo Z. 2004. Isoflurane preconditioning induces neuroprotection against ischemia via activation of p38 mitogen-activated protein kinase. Mol Pharmacol 65:1172-1180.